Bill Sponsor
House Bill 2700
116th Congress(2019-2020)
Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act
Introduced
Introduced
Introduced in House on May 14, 2019
Overview
Text
Introduced
May 14, 2019
Latest Action
Jun 26, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
2700
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act

This bill addresses prescription drugs and extends several health care, research, and workforce programs.

Currently, a generic drug manufacturer is awarded 180 days of exclusivity on the market if it is the first applicant to file an application with the Food and Drug Administration (FDA), and the exclusivity period begins upon the first applicant's commercial marketing. The bill authorizes the FDAto approve a subsequent generic drug application prior to the first applicant's first date of commercial marketing if certain conditions are met.

The bill prohibits a brand-name, generic, or biosimilar drug manufacturer from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exclusions, is a violation of the bill if the filer of the subsequent generic application receives something of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biological product.

The developer of a drug or biological product, such as a generic or biosimilar version of a drug, may bring a civil action against the license holder of an approved drug if the holder has declined to make available sufficient quantities of the approved drug for the developer's testing.

The bill also extends several health care, research, and workforce programs, including the National Health Service Corps, through FY2020.

Text (1)
Actions (5)
06/26/2019
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
06/26/2019
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
05/15/2019
Referred to the Subcommittee on Health.
05/14/2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
05/14/2019
Introduced in House
Public Record
Record Updated
Feb 8, 2022 11:14:47 PM